Medical use of cannabis and cannabinoids

December 4th: The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has produced a report on the evidence base for the medical use of cannabis and cannabinoids. The report outlines the importance of distinguishing cannabis preparations and medicine products and summarises regulations within the EU. 

cannabis graph

As most EU countries now allow, or are considering allowing, the medical use of cannabis or cannabinoids in some form, the report is designed to help policy-makers practitioners, potential patients and the public, to understand the scientific, clinical and regulatory issues that arise when consideration is given to making cannabis or cannabinoids available to treat the symptoms of medical illnesses. The report highlights the challenges of decision-making in this area and summarises the multiple issues that governments may consider when deciding whether to make cannabis or cannabinoids available for medical use. These include: the types of product that patients will be allowed to use; the medical conditions for which such products can be used; and the type of medical and regulatory supervision under which patients are allowed to use them. The report is available as a download.

 © DLR - DATF, 2016   C/O Southside Partnership, Main st., Blackrock, Co. Dublin Tel: 01-7060125 / 087-6494922